Beam Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, reporting a net loss of $122.7 million, or $1.18 per share, compared to a net loss of $102.1 million in the prior year period. The company held $1.2 billion in cash and marketable securities as of June 30, 2026, with a runway expected to support operations into mid-2029. Clinically, Beam dosed the first patient in the global pivotal cohort for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) and completed dosing of all adult and adolescent patients in the Phase 1/2 BEACON trial for risto-cel in sickle cell disease. The company also received FDA clearance for the IND application for BEAM-304 in phenylketonuria (PKU). Beam Therapeutics is a biotechnology company developing precision genetic medicines through base editing.

Beam Therapeutics Inc. held its 2026 annual meeting of stockholders on June 3, 2026, and reported the voting results for director elections, the ratification of Deloitte & Touche LLP as independent auditor, and executive compensation. The elected Class III directors are John Evans, John Maraganore, Ph.D., and Christi Shaw.